Investors & Media

What’s new.

Press releases

Press releases.

April 29th 2025

Immutep Quarterly Activities Report Q3 FY25

April 2nd 2025

Immutep to Participate in Upcoming Investor Conferences

March 25th 2025

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

March 25th 2025

Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

March 25th 2025

Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

March 4th 2025

Canaccord Genuity - 1H25 model update: All eyes on next HNSCC update; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

more